Clinical Trial: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
Brief Summary: The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
Detailed Summary:
Sponsor: XBiotech, Inc.
Current Primary Outcome: Change in Physician's Wound Assessment & Patient's Global Assessment [ Time Frame: 28 days ]
Original Primary Outcome: Change in Physician's Global Assessment [ Time Frame: 28 days ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: XBiotech, Inc.
Dates:
Date Received: October 15, 2013
Date Started: January 2014
Date Completion:
Last Updated: January 23, 2017
Last Verified: January 2017